Literature DB >> 33261057

Artificial Intelligence Tools for Refining Lung Cancer Screening.

J Luis Espinoza1,2, Le Thanh Dong3.   

Abstract

Nearly one-quarter of all cancer deaths worldwide are due to lung cancer, making this disease the leading cause of cancer death among both men and women. The most important determinant of survival in lung cancer is the disease stage at diagnosis, thus developing an effective screening method for early diagnosis has been a long-term goal in lung cancer care. In the last decade, and based on the results of large clinical trials, lung cancer screening programs using low-dose computer tomography (LDCT) in high-risk individuals have been implemented in some clinical settings, however, this method has various limitations, especially a high false-positive rate which eventually results in a number of unnecessary diagnostic and therapeutic interventions among the screened subjects. By using complex algorithms and software, artificial intelligence (AI) is capable to emulate human cognition in the analysis, interpretation, and comprehension of complicated data and currently, it is being successfully applied in various healthcare settings. Taking advantage of the ability of AI to quantify information from images, and its superior capability in recognizing complex patterns in images compared to humans, AI has the potential to aid clinicians in the interpretation of LDCT images obtained in the setting of lung cancer screening. In the last decade, several AI models aimed to improve lung cancer detection have been reported. Some algorithms performed equal or even outperformed experienced radiologists in distinguishing benign from malign lung nodules and some of those models improved diagnostic accuracy and decreased the false-positive rate. Here, we discuss recent publications in which AI algorithms are utilized to assess chest computer tomography (CT) scans imaging obtaining in the setting of lung cancer screening.

Entities:  

Keywords:  artificial intelligence and lung cancer; computers assisted diagnosis; early cancer diagnosis; lung cancer imaging; lung cancer screening

Year:  2020        PMID: 33261057     DOI: 10.3390/jcm9123860

Source DB:  PubMed          Journal:  J Clin Med        ISSN: 2077-0383            Impact factor:   4.241


  2 in total

1.  Human-level COVID-19 diagnosis from low-dose CT scans using a two-stage time-distributed capsule network.

Authors:  Parnian Afshar; Moezedin Javad Rafiee; Farnoosh Naderkhani; Shahin Heidarian; Nastaran Enshaei; Anastasia Oikonomou; Faranak Babaki Fard; Reut Anconina; Keyvan Farahani; Konstantinos N Plataniotis; Arash Mohammadi
Journal:  Sci Rep       Date:  2022-03-22       Impact factor: 4.379

2.  A Classifier for Improving Early Lung Cancer Diagnosis Incorporating Artificial Intelligence and Liquid Biopsy.

Authors:  Maosong Ye; Lin Tong; Xiaoxuan Zheng; Hui Wang; Haining Zhou; Xiaoli Zhu; Chengzhi Zhou; Peige Zhao; Yan Wang; Qi Wang; Li Bai; Zhigang Cai; Feng-Ming Spring Kong; Yuehong Wang; Yafei Li; Mingxiang Feng; Xin Ye; Dawei Yang; Zilong Liu; Quncheng Zhang; Ziqi Wang; Shuhua Han; Lihong Sun; Ningning Zhao; Zubin Yu; Juncheng Zhang; Xiaoju Zhang; Ruth L Katz; Jiayuan Sun; Chunxue Bai
Journal:  Front Oncol       Date:  2022-03-02       Impact factor: 6.244

  2 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.